

► PŘEHLEDOVÉ ČLÁNKY

NOVINKY V LÉČBĚ MYASTHENIA GRAVIS

One. 2022;17(6):e0269749. doi:10.1371/journal.pone.0269749.

7. Harris L, Allman PH, Sheffield R, Cutter G. Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States. *J Clin Neuromuscul Dis.* 2020;22(1):11-21. doi:10.1097/CND.0000000000000301.

8. Hewett K, Sanders DB, Grove RA, et al. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. *Neurology.* 2018;90(16):e1425-e1434. doi:10.1212/WNL.0000000000005323.

9. Howard J, Bril V, Vu T, et al. Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study (4520). *Neurology.* 2021;96(15 Supplement).

10. Howard JF, Bresch S, Genge A, et al. Safety and Efficacy of Zilucoplan in Patients with Generalised Myasthenia Gravis (RAISE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. *The Lancet Neurology.* 2023;22(5):395-406. [https://doi.org/10.1016/S1474-4422\(23\)00080-7](https://doi.org/10.1016/S1474-4422(23)00080-7).

11. Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. *Lancet Neurol.* 2017;16(12):976-986. doi:10.1016/S1474-4422(17)30369-1.

12. Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. *Ann Thorac Surg.* 2000;70(1):16-23. doi:10.1212/wnl.55.1.16.

13. Lysák D. Imunoterapie pomocí CAR T-lymfocytů. *Onkologie.* 2015;9(1):13-18.

14. Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: Clinical signposts and treatment strategies. *Ther Adv Neurol Disord.* 2018;11. doi:10.1177/1756285617749134.

15. McKeage K. Ravulizumab: First Global Approval. *Drugs.* 2019;79(3):347-352. doi:10.1007/s40265-019-01068-2.

16. Menon D, Barnett C, Bril V. Novel Treatments in Myasthenia Gravis. *Front Neurol.* 2020;11. doi:10.3389/fneur.2020.00538.

17. Menon D, Bril V. Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. *Drugs.* 2022;82(8):865-887. doi:10.1007/s40265-022-01726-y.

18. Murai H, Uzawa A, Suzuki Y, et al. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. *J Neurol Sci.* 2019;407:116419. doi:10.1016/j.jns.2019.08.004.

19. Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. *Neurology.* 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124.

20. Ndegwa S, Mierzwiński-Urban M. Emerging Drugs for Generalized Myasthenia Gravis. *Can J Heal Technol.* 2022;2(2):114-122. doi:10.51731/cjht.2022.270.

21. Nowak RJ, Coffey CS, Goldstein JM, et al. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. *Neurology.* 2022;98(4):e376-e389. doi:10.1212/WNL.0000000000013121.

22. Oh S, O'Connor K, Payne A. MuSK Chimeric Autoantibody

Receptor (CAAR) T Cells for Antigen-specific Cellular Immunotherapy of Myasthenia Gravis (2769). *Neurology.* 2020;94(15 Supplement).

23. Sánchez-Tejerina D, Sotoca J, Llauro A, et al. New Targeted Agents in Myasthenia Gravis and Future Therapeutic Strategies. *J Clin Med.* 2022;11(21):6394. doi:10.3390/jcm11216394.

24. Schneider-Gold C, Reinacher-Schick A, Ellrichmann G, Gold R. Bortezomib in severe MuSK-antibody positive myasthenia gravis: First clinical experience. *Ther Adv Neurol Disord.* 2017;10(10):339-341. doi:10.1177/1756285617721093.

25. SÚKL Státní ústav pro kontrolu léčiv [online]. Dostupné z: <https://prehledy.sukl.cz/>.

26. Tandan R, Hehir MK, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: A systematic review. *Muscle and Nerve.* 2017;56(2):185-196. doi:10.1002/mus.25597.

27. Tannemaat MR, Verschuuren JJGM. Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids. *Neuromuscul Disord.* 2020;30(2):111-119. doi:10.1016/j.nmd.2019.12.003.

28. Týblová M. Current and future therapeutic options for the treatment of the generalized form of myasthenia gravis. *Ces a Slov Neurol a Neurochir.* 2023;86(2):100-106. doi:10.48095/cc-snn2023100.

29. U.S. National Library of Medicine [online]. Dostupné z: <https://classic.clinicaltrials.gov/>.

30. Ward ES, Gelin D, Dreesen E, et al. Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders. *Front Immunol.* 2022;13(June):1-13. doi:10.3389/fimmu.2022.892534.

Chcete číst aktuální články časopisu **Neurologie pro praxi ON-LINE?**

Řešením je ELEKTRONICKÉ PŘEDPLATNÉ

- na **www.neurologiepropraxi.cz** ČTĚTE IHNEDE v podobě listovačky či ve formátu PDF
- bez přihlášení/předplatného jsou články přístupné až **po 1 roce**
- **6 čísel/rok – 1008 Kč** (vč. tematických příloh)

Objednávejte
v našem e-shopu →



www.solen.cz

